Our goal is to understand how nutrient-responsive signaling pathways can be harnessed to promote health and longevity. Rapamycin, an inhibitor of the protein kinase mTOR, can improve both health and longevity in model organisms including mammals. Understanding and manipulating the mTOR signaling pathway through dietary, pharmaceutical or genetic interventions may provide insight into the treatment of age-related diseases, including diabetes, Alzheimer’s disease, cancer, and Hutchinson-Gilford Progeria Syndrome.

The Lamming lab is supported in part by the NIH National Institute on Aging and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Other recent sources of support include the American Federation For Aging Research, the Glenn Foundation for Medical Research, the Progeria Research Foundation, and the Wisconsin Partnership Program.

Postdoctoral, Ph.D. students, M.D. students and undergraduates interested in pursuing research in the Lamming lab should contact Dr. Lamming directly at dlamming@medicine.wisc.edu.